Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to define the safety profile and maximum tolerated
dose (MTD) of sorafenib tablets in combination with carboplatin and paclitaxel chemotherapy
in patients with advanced, refractory solid tumors.
The secondary objectives were evaluation of pharmacokinetics (PK) and tumor response of these
patients being treated with sorafenib in combination with paclitaxel and carboplatin.